AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
_6ff029a61766633234293.png?format=webp&width=1186&height=250)
Palisade Bio Soars 13% on Clinical Trial Progress
Generated by AI AgentAinvest Pre-Market Radar
Tuesday, Jul 22, 2025 5:18 am ET1min read
Aime SummaryPalisade Bio's stock surged by 12.99% in pre-market trading on July 22, 2025, marking a significant rise that has caught the attention of investors and analysts alike.
Palisade Bio has made substantial progress in its clinical trials, having initiated a Phase 1b multiple-ascending dose study in patients with ulcerative colitis following the successful completion of Phase 1a. This development is a crucial step forward in the company's efforts to bring novel peptide-based therapeutics to market.
The company's recent earnings report for Q2 2025 highlights its focus on the discovery and development of innovative treatments, further solidifying its position as a key player in the biotechnology sector. The report underscores Palisade Bio's commitment to advancing its pipeline and delivering value to shareholders.
Ainvest Pre-Market Radar
Get the scoop on pre-market movers and shakers in the US stock market.
Latest Articles
Sweetgreen (SG) Surged 5.41% in Pre-Market Trading on Strategic Expansion into Sacramento
Dec.26 2025
United States Antimony Surges 5.31% on Landmark DLA and Commercial Supply Contracts
Dec.26 2025
United States Antimony surges 5.31% on sharp reversal in investor sentiment ahead of session open.
Dec.26 2025
Autozi Internet surges 13.54% in pre-market trading as AI expansion and EV partnerships boost investor confidence.
Dec.26 2025
Strive Asset Management ASST surged 7.03% driven by 12.25% dividend hike and Bitcoin treasury strategy
Dec.26 2025
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet